Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...

The cause of death has been released for a 38-year-old Super Bowl-champion team linebacker. Bryan Braman was part of the ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

The deal, announced on June 30, will advance a subsect of research into new autoimmune treatments that began at Penn.

Traditional ex-vivo CAR-T therapies require extracting a patient’s T cells, engineering them in specialized labs, and ...

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and ...

RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.

Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of ...

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor ...

Prof. LIANG Xingjie's team from the National Center for Nanoscience and Technology, along with Prof. GONG Ningqiang from the University of Science and Technology of China, has developed a biomimetic ...